search
Back to results

Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

Primary Purpose

Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Web/mobile/tablet-based digital decision aid + communication (DA+C) tool
Sponsored by
University of Massachusetts, Worcester
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hemorrhagic Stroke, Intracerebral focused on measuring shared decision making, physician-family communication, withdrawal of life sustaining therapies, patient-value congruent care, decision aid, neuroICU, neurocritical care

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria for surrogates and patients: surrogate is age 18 years or older, no upper age limit; documented surrogate decision-maker (official health care proxy, or legal next of kin) of a critically ill severe acute brain injury (SABI) patient ≥ 3 days after admission; patient is age 18 years or older, no upper age limit; patient has SABI; defined as either traumatic brain injury, spontaneous primary intracerebral hemorrhage (not due to tumor or vascular malformation), or hemispheric acute ischemic stroke; patient is"critically ill" defined as either intubated on a mechanical ventilator, or unable to swallow without a feeding tube (even if not intubated/ventilated); patient is judged by the attending physician to have ≥40% risk of death or long-term functional impairment, elicited by asking the attending physician, "does this patient have at least a 40% chance of in-hospital mortality or long-term functional impairment?", defined as needing assistance with at least 1 activity of daily living (ADL). patient has undergone initial stabilization but remains critically ill; surrogate will participate in clinician-family goals of care meeting, either in person or via video- or telephone-conference. surrogate must be English speaking and literate Exclusion Criteria for surrogates and patients: devastating patients with severe SABI who die early (within the first 3 days after admission); surrogate decision-maker is non-English speaking; surrogate decision-maker is illiterate. Inclusion criteria for clinicians: clinical treating attending, or physician trainee (fellow, resident), or licensed affiliated practitioner who will lead the clinician-family meeting when goals-of-care are discussed; clinician may decline participation in the outcome measures but cannot restrict the surrogate decision-maker in study participation. Exclusion criteria for clinicians: - unwillingness to comply with study protocol.

Sites / Locations

  • Johns Hopkins Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Web-based Decision Aid + Communication (DA+C) tool

Usual Care

Arm Description

Surrogate(s) will read/click through the DA+C tool prior to the clinician-family meeting and complete the integrated worksheet. Surrogate(s) will have unlimited access to the DA+C tool and may return to the tool and edit the worksheet at any time.

No decision aid

Outcomes

Primary Outcome Measures

Feasibility of tool use by surrogate decision-makers
Data tracking analytics built into the tool will be employed to determine the extent to which the tools is used as per protocol.
Feasibility of enrolling surrogates in a stepped-wedge (before/after) clinical trial in a neurocritical care setting
Measured by meeting target enrollment.
Feasibility of retaining surrogates in a neurocritical care setting
The number of subjects that complete the long-term follow-up.

Secondary Outcome Measures

Participants' ratings of usability of the tool (Intervention surrogates only)
Usability of the tool as measured with the System Usability Scale.
Participants' ratings of perceived effectiveness of the tool in preparing them for decision-making (Intervention surrogates only)
Perceived Effectiveness will be measured with an 11-item perceived effectiveness questionnaire using a 5-point Likert scale.
Fidelity to intervention protocol
Fidelity to the intervention protocol will be measured using self-checklists by clinicians and review of a random selection of 30% of the audio-recorded clinician-family meetings

Full Information

First Posted
January 3, 2023
Last Updated
October 10, 2023
Sponsor
University of Massachusetts, Worcester
Collaborators
Worcester Polytechnic Institute, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Johns Hopkins University
search

1. Study Identification

Unique Protocol Identification Number
NCT05671874
Brief Title
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
Official Title
Pilot Trial of a Web/Mobile/Tablet-based Communication and Goals-of-Care Decision Aid for Clinicians and Families of Severe Acute Brain Injury Patients
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 23, 2023 (Anticipated)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Massachusetts, Worcester
Collaborators
Worcester Polytechnic Institute, National Institutes of Health (NIH), National Institute of Nursing Research (NINR), Johns Hopkins University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain injury (SABI), including those with moderate-severe traumatic brain injury, large hemispheric acute ischemic stroke and intracerebral hemorrhage.
Detailed Description
Every 30 seconds an adult in the U.S. suffers a severe acute brain injury (SABI) from traumatic brain injury or large ischemic or hemorrhagic stroke, resulting in 200,000 deaths and >900,000 survivors living with disability annually. Every day, surrogate decision-makers face the difficult "goals of care" decision in intensive care units (ICUs) to continue or withdraw life support while considering the patient's long-term prognosis. In this study, we will pilot test a pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogates of patients with SABI in ICUs. These problems are an important target for intervention, because they contribute to 3 major clinical and public health issues: 1) family members struggle in the role of surrogate, leading to lasting symptoms of psychological distress; 2) clinicians are poorly trained in communicating prognosis after SABI, often doing so with variability and bias, inadequately preparing families for their decisions; 3) patients often receive burdensome treatments that they would not choose. Decision aids improve the quality of patients' decisions based on a large evidence-base, but no empirically validated tools currently exist for surrogate decision-making in SABI patients at high risk for death or disability. This is problematic because surrogates of SABI patients are unprepared for the difficult decisions about the use of life support and patients' potential long-term disability, which hinge on both medical information and the patient's values and preferences. We have developed and refined a tailored digital, web-based decision aid (DA) for families of critically ill SABI patients, conceptually grounded in the Ottawa Decision Support Framework, to enhance, not replace, clinician-family communication. We will leverage a digital platform, which is portable and shareable among family members when geographically distant or not allowed to visit the ICU (as during the COVID-19 pandemic) and allows integration of videos to reach lower-literacy groups. This innovative tool challenges the existing paradigm for decision-making in SABI patients. This pilot study among 50 surrogates of SABI patients and their clinicians will assess the feasibility of deploying the web-based tool as well as to explore the tools impact on measures of communication and decision-quality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury
Keywords
shared decision making, physician-family communication, withdrawal of life sustaining therapies, patient-value congruent care, decision aid, neuroICU, neurocritical care

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
stepped-wedge randomized trial (before-after study)
Masking
Outcomes Assessor
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Web-based Decision Aid + Communication (DA+C) tool
Arm Type
Experimental
Arm Description
Surrogate(s) will read/click through the DA+C tool prior to the clinician-family meeting and complete the integrated worksheet. Surrogate(s) will have unlimited access to the DA+C tool and may return to the tool and edit the worksheet at any time.
Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
No decision aid
Intervention Type
Behavioral
Intervention Name(s)
Web/mobile/tablet-based digital decision aid + communication (DA+C) tool
Intervention Description
The web/mobile/tablet-based digital DA+C toll is designed to enhance communication and shared decision making between clinicians and surrogates of critically ill severe acute brain injury (SABI) with four goals: to 1) prepare families for their surrogate role and discussions with clinicians; 2) provide balanced information to families on prognosis and all available treatment options; 3) provide tailored information about the patient and family to clinicians in advance of family meetings; and 4) serve as a communication guide for clinicians in the clinician-family meeting to facilitate shared decision-making.
Primary Outcome Measure Information:
Title
Feasibility of tool use by surrogate decision-makers
Description
Data tracking analytics built into the tool will be employed to determine the extent to which the tools is used as per protocol.
Time Frame
Duration of ICU stay, an expected average of 4 weeks
Title
Feasibility of enrolling surrogates in a stepped-wedge (before/after) clinical trial in a neurocritical care setting
Description
Measured by meeting target enrollment.
Time Frame
Through study completion, estimated 18 months past primary start date
Title
Feasibility of retaining surrogates in a neurocritical care setting
Description
The number of subjects that complete the long-term follow-up.
Time Frame
Three-months post SABI
Secondary Outcome Measure Information:
Title
Participants' ratings of usability of the tool (Intervention surrogates only)
Description
Usability of the tool as measured with the System Usability Scale.
Time Frame
Duration of ICU stay, an expected average of 4 weeks
Title
Participants' ratings of perceived effectiveness of the tool in preparing them for decision-making (Intervention surrogates only)
Description
Perceived Effectiveness will be measured with an 11-item perceived effectiveness questionnaire using a 5-point Likert scale.
Time Frame
Duration of ICU stay, an expected average of 4 weeks
Title
Fidelity to intervention protocol
Description
Fidelity to the intervention protocol will be measured using self-checklists by clinicians and review of a random selection of 30% of the audio-recorded clinician-family meetings
Time Frame
Through study completion, estimated 18 months past primary start date
Other Pre-specified Outcome Measures:
Title
Participants' ratings of what they liked and disliked about the DA+C tool (Intervention surrogates only)
Description
Measured by two open ended questions from the Acceptability Scale.
Time Frame
Until right before the scheduled clinician-family meeting, an average of 10-14 days after admission
Title
Surrogates' clarity about patient values & preferences
Description
We will apply the 3-item Values Clarity Subscale of the Decisional Conflict Scale.
Time Frame
After the scheduled clinician-family meeting, an average of 10-14 days after admission
Title
Surrogates' ratings of the degree of shared decision-making
Description
We will apply six questions from Quality of Communication Scale pertaining to shared decision-making.
Time Frame
After the scheduled clinician-family meeting, an average of 10-14 days after admission
Title
Caregiver Burden
Description
Measured with the 5-item short form of the Caregiver Burden Scale.
Time Frame
Three-months post SABI
Title
Decision Regret
Description
Measured using the Decision Regret Scale.
Time Frame
Three-months post SABI
Title
Goals-of-care decision
Description
Final goals-of-care decision by surrogates (survival vs. withdrawal of life sustaining treatments)
Time Frame
Hospital discharge up until 3-months post SABI
Title
Mortality
Description
Patient death
Time Frame
Hospital discharge up until 3-months post SABI
Title
Functional status
Description
We will measure basic activities of daily living with the Glasgow Outcome Scale Extended (GOSE; range 1-8) and the modified Rankin Scale (range 0-6)
Time Frame
3-months post SABI
Title
Patient-perceived Patient- Centeredness of Care
Description
To assess patient centeredness of care adapted for use by surrogates
Time Frame
3-months post SABI

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria for surrogates and patients: surrogate is age 18 years or older, no upper age limit; documented surrogate decision-maker (official health care proxy, or legal next of kin) of a critically ill severe acute brain injury (SABI) patient ≥ 3 days after admission; patient is age 18 years or older, no upper age limit; patient has SABI; defined as either traumatic brain injury, spontaneous primary intracerebral hemorrhage (not due to tumor or vascular malformation), or hemispheric acute ischemic stroke; patient is"critically ill" defined as either intubated on a mechanical ventilator, or unable to swallow without a feeding tube (even if not intubated/ventilated); patient is judged by the attending physician to have ≥40% risk of death or long-term functional impairment, elicited by asking the attending physician, "does this patient have at least a 40% chance of in-hospital mortality or long-term functional impairment?", defined as needing assistance with at least 1 activity of daily living (ADL). patient has undergone initial stabilization but remains critically ill; surrogate will participate in clinician-family goals of care meeting, either in person or via video- or telephone-conference. surrogate must be English speaking and literate Exclusion Criteria for surrogates and patients: devastating patients with severe SABI who die early (within the first 3 days after admission); surrogate decision-maker is non-English speaking; surrogate decision-maker is illiterate. Inclusion criteria for clinicians: clinical treating attending, or physician trainee (fellow, resident), or licensed affiliated practitioner who will lead the clinician-family meeting when goals-of-care are discussed; clinician may decline participation in the outcome measures but cannot restrict the surrogate decision-maker in study participation. Exclusion criteria for clinicians: - unwillingness to comply with study protocol.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Susanne Muehlschlegel, MD, MPH
Phone
(617)866-8289
Email
susanne.muehlschlegel@umassmed.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Susanne Muehlschlegel, MD, MPH
Phone
(410)502-6534
Email
smuehlsch@jhu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susanne Muehlschlegel, MD, MPH
Organizational Affiliation
University of Massachusetts Chan Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins Hospital
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21218
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susanne Muehlschlegel, MD, MPH
Phone
617-866-8289
Email
smuehlsch@jhu.edu
First Name & Middle Initial & Last Name & Degree
Susanne Muehlschlegel, MD, MPH
Phone
(410) 5026534
Email
smuehlsch@jhu.edu
First Name & Middle Initial & Last Name & Degree
Susanne Muehlschlegel, MD, MPH

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Anonymized data not published within the final manuscript will be made available by request from any qualified investigator.
IPD Sharing Time Frame
After publication of the main manuscript up until 5 years after publication.
IPD Sharing Access Criteria
Requests should be made to the principal investigator susanne.muehlschlegel[at]umassmed.edu.
Citations:
PubMed Identifier
35853748
Citation
Muehlschlegel S, Goostrey K, Flahive J, Zhang Q, Pach JJ, Hwang DY. A Pilot Randomized Clinical Trial of a Goals-of-Care Decision Aid for Surrogates of Severe Acute Brain Injury Patients. Neurology. 2022 Jul 19;99(14):e1446-55. doi: 10.1212/WNL.0000000000200937. Online ahead of print.
Results Reference
background
PubMed Identifier
33786434
Citation
Goostrey KJ, Lee C, Jones K, Quinn T, Moskowitz J, Pach JJ, Knies AK, Shutter L, Goldberg R, Mazor KM, Hwang DY, Muehlschlegel S. Adapting a Traumatic Brain Injury Goals-of-Care Decision Aid for Critically Ill Patients to Intracerebral Hemorrhage and Hemispheric Acute Ischemic Stroke. Crit Care Explor. 2021 Mar 9;3(3):e0357. doi: 10.1097/CCE.0000000000000357. eCollection 2021 Mar.
Results Reference
background
PubMed Identifier
35265851
Citation
Muehlschlegel S, Perman SM, Elmer J, Haggins A, Teixeira Bailey ND, Huang J, Jansky L, Kirchner J, Kasperek-Wynn R, Lipman PD, Yeatts SD, Fetters MD, Dickert NW, Silbergleit R. The Experiences and Needs of Families of Comatose Patients After Cardiac Arrest and Severe Neurotrauma: The Perspectives of National Key Stakeholders During a National Institutes of Health-Funded Workshop. Crit Care Explor. 2022 Mar 4;4(3):e0648. doi: 10.1097/CCE.0000000000000648. eCollection 2022 Mar.
Results Reference
background
PubMed Identifier
35696329
Citation
Goostrey K, Muehlschlegel S. Prognostication and shared decision making in neurocritical care. BMJ. 2022 Apr 7;377:e060154. doi: 10.1136/bmj-2021-060154.
Results Reference
background
PubMed Identifier
32554766
Citation
Muehlschlegel S, Hwang DY, Flahive J, Quinn T, Lee C, Moskowitz J, Goostrey K, Jones K, Pach JJ, Knies AK, Shutter L, Goldberg R, Mazor KM. Goals-of-care decision aid for critically ill patients with TBI: Development and feasibility testing. Neurology. 2020 Jul 14;95(2):e179-e193. doi: 10.1212/WNL.0000000000009770. Epub 2020 Jun 17.
Results Reference
background

Learn more about this trial

Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

We'll reach out to this number within 24 hrs